Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma

被引:20
作者
Higashi, Morihiro [1 ]
Tokuhira, Michihide [2 ]
Fujino, Satoshi [1 ]
Yamashita, Takahisa [1 ]
Abe, Keiko [1 ]
Arai, Eiichi [1 ]
Kizaki, Masahiro [2 ]
Tamaru, Jun-ichi [1 ]
机构
[1] Saitama Med Univ, Dept Pathol, Saitama Med Ctr, Saitama, Japan
[2] Saitama Med Univ, Dept Hematol, Saitama Med Ctr, Saitama, Japan
关键词
Diffuse large B-cell lymphoma; HLA-DR; tumor microenvironment; REGULATORY T-CELLS; TISSUE MICROARRAY; GENE; CANCER; SURVIVAL; PHENOTYPE; PROGNOSIS; IMPACT; FOXP3; CHOP;
D O I
10.3109/10428194.2015.1038708
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The interaction between tumor cells and the tumor microenvironment is essential in the development and progression of diffuse large B-cell lymphoma (DLBCL). Loss of human leukocyte antigen DR (HLA-DR) in DLBCL is a robust adverse prognostic marker. We evaluated the immunohitochemical expression of HLA-DR in lymphoma and the biologic implications of the loss of HLA-DR. The loss of HLA-DR correlated with clinical stage (p < 0.05), International Prognosis Index (p < 0.05), soluble interleukin-2 receptor (p < 0.05) and poor outcome in patients with DLBCL, especially among elderly patients. Flow cytometry analysis of the infiltrating T-cells showed that the mean CD4 + CD25 +/CD8 ratio of the infiltrating T-cells was higher in the HLA-DR positive group than in the HLA-DR negative group (p < 0.05). These data suggest that loss of HLA-DR expression in DLBCL decreases the ratio of helper T-cell within the T-cell population in the tumor microenvironment and might contribute to escape from immunosurveillance.
引用
收藏
页码:161 / 166
页数:6
相关论文
共 31 条
  • [1] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
    Alizadeh, AA
    Eisen, MB
    Davis, RE
    Ma, C
    Lossos, IS
    Rosenwald, A
    Boldrick, JG
    Sabet, H
    Tran, T
    Yu, X
    Powell, JI
    Yang, LM
    Marti, GE
    Moore, T
    Hudson, J
    Lu, LS
    Lewis, DB
    Tibshirani, R
    Sherlock, G
    Chan, WC
    Greiner, TC
    Weisenburger, DD
    Armitage, JO
    Warnke, R
    Levy, R
    Wilson, W
    Grever, MR
    Byrd, JC
    Botstein, D
    Brown, PO
    Staudt, LM
    [J]. NATURE, 2000, 403 (6769) : 503 - 511
  • [2] Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials
    Bernd, Heinz-Wolfram
    Ziepert, Marita
    Thorns, Christoph
    Klapper, Wolfram
    Wacker, Hans-Heinrich
    Hummel, Michael
    Stein, Harald
    Hansmann, Martin-Leo
    Ott, German
    Rosenwald, Andreas
    Mueller-Hermelink, Hans-Konrad
    Barth, Thomas F. E.
    Moeller, Peter
    Cogliatti, Sergio B.
    Pfreundschuh, Michael
    Schmitz, Norbert
    Truemper, Lorenz
    Hoeller, Silvia
    Loeffler, Markus
    Feller, Alfred C.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (11): : 1569 - 1580
  • [3] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier, B
    Lepage, E
    Brière, J
    Herbrecht, R
    Tilly, H
    Bouabdallah, R
    Morel, P
    Van den Neste, E
    Salles, G
    Gaulard, P
    Reyes, F
    Gisselbrecht, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) : 235 - 242
  • [4] The challenge of the microenvironment in B-cell lymphomas
    Coupland, Sarah E.
    [J]. HISTOPATHOLOGY, 2011, 58 (01) : 69 - 80
  • [5] Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications - A study from the Lunenburg Lymphoma Biomarker Consortium
    de Jong, Daphne
    Rosenwald, Andreas
    Chhanabhai, Mukesh
    Gaulard, Philippe
    Klapper, Wolfram
    Lee, Abigail
    Sander, Birgitta
    Thorns, Christoph
    Campo, Elias
    Molina, Thierry
    Norton, Andrew
    Hagenbeek, Anton
    Horning, Sandra
    Lister, Andrew
    Raemaekers, John
    Gascoyne, Randy D.
    Salles, Gilles
    Weller, Edie
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (07) : 805 - 812
  • [6] Microenvironmental Protection in Diffuse Large-B-Cell Lymphoma
    Eng, Charis
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (22) : 2379 - 2381
  • [7] Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma
    Glowala-Kosinska, Magdalena
    Chwieduk, Agata
    Nieckula, Jaroslaw
    Sadus-Wojciechowska, Maria
    Grosicki, Sebastian
    Rusin, Aleksandra
    Nowara, Elzbieta
    Giebel, Sebastian
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2013, 91 (02) : 122 - 128
  • [8] Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
    Hans, CP
    Weisenburger, DD
    Greiner, TC
    Gascoyne, RD
    Delabie, J
    Ott, G
    Müller-Hermelink, HK
    Campo, E
    Braziel, RM
    Jaffe, ES
    Pan, ZG
    Farinha, P
    Smith, LM
    Falini, B
    Banham, AH
    Rosenwald, A
    Staudt, LM
    Connors, JM
    Armitage, JO
    Chan, WC
    [J]. BLOOD, 2004, 103 (01) : 275 - 282
  • [9] Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab era
    Hanzawa, Kyoko
    Momose, Shuji
    Higashi, Morihiro
    Tokuhira, Michihide
    Watanabe, Reiko
    Kajino, Kazunori
    Hino, Okio
    Itoyama, Shinji
    Kizaki, Masahiro
    Tamaru, Jun-Ichi
    [J]. LEUKEMIA & LYMPHOMA, 2010, 51 (11) : 2054 - 2062
  • [10] Control of regulatory T cell development by the transcription factor Foxp3
    Hori, S
    Nomura, T
    Sakaguchi, S
    [J]. SCIENCE, 2003, 299 (5609) : 1057 - 1061